期刊
METABOLIC BRAIN DISEASE
卷 33, 期 4, 页码 1131-1139出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11011-018-0221-7
关键词
Tacrine(10)-hupyridone; Acetylcholinesterase; Alzheimer's disease; Scopolamine; Dual-binding
资金
- National Natural Science Foundation of China [81673407, U1503223]
- Research Project on Nonprofit Technology of Zhejiang Province [2016C37110]
- Ningbo international science and technology cooperation project [2014D10019]
- Ningbo municipal innovation team of life science and health [2015C110026]
- Guangdong Provincial International Cooperation Project of Science Technology [2013B051000038]
- Shenzhen Basic Research Program [JCYJ20160331141459373]
- Guangdong-Hong Kong Technology Cooperation Funding Scheme [GHP/012/16GD]
- Research Grants Council of Hong Kong [15101014]
- Hong Kong Polytechnic University [G-YBGQ, G-YZ95]
- LiDakSum Marine Biopharmaceutical Development Fund
- K. C. Wong Magna Fund in Ningbo University
Tacrine(10)-hupyridone (A10E) was designed as a dual-binding acetylcholinesterase (AChE) inhibitor from the modification of tacrine and a fragment of huperzine A. We have found that A10E effectively inhibited AChE in a mixed competitive manner, with an IC50 of 26.4 nM, which is more potent than those of tacrine and huperzine A. Most importantly, we have shown, for the first time that A10E attenuated scopolamine-induced cognitive impairments without affecting motor function in mice. A10E effectively attenuated impairments of learning and memory to a similar extent as donepezil, an inhibitor of AChE used for treating Alzheimer's disease (AD). In addition, A10E significantly decreased AChE activity in the brain of mice, suggesting that A10E might cross the brain blood-barrier. Taken together, our results demonstrated that A10E, a designed dual-binding AChE inhibitor, could effectively reverse cognitive impairments, indicating that A10E might provide therapeutic efficacy for AD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据